» Articles » PMID: 38230293

Gender Differences in Pharmacokinetics: A Perspective on Contrast Agents

Abstract

Gender is an important risk factor for adverse drug reactions. Women report significantly more adverse drug reactions than men. There is a growing consensus that gender differences in drug PK is a main contributor to higher drug toxicity in women. These differences stem from physiological differences (body composition, plasma protein concentrations, and liver and kidney function), drug interactions, and comorbidities. Contrast agents are widely used to enhance diagnostic performance in computed tomography and magnetic resonance imaging. Despite their broad use, these contrast agents can lead to important adverse reactions including hypersensitivity reactions, nephropathy, and hyperthyroidism. Importantly, female gender is one of the main risk factors for contrast agent toxicity. As these adverse reactions may be related to gender differences in PK, this perspective aims to describe distribution and elimination pathways of commonly used contrast agents and to critically discuss gender differences in these processes.

Citing Articles

Improving Individualized Salbutamol Treatment: A Population Pharmacokinetic Model for Oral Salbutamol in Virtual Patients.

Marques L, Vale N Pharmaceutics. 2025; 17(1.

PMID: 39861686 PMC: 11768577. DOI: 10.3390/pharmaceutics17010039.


A PopPBPK-RL approach for precision dosing of benazepril in renal impaired patients.

Vigueras G, Munoz-Gil L, Reinisch V, Pinto J J Pharmacokinet Pharmacodyn. 2024; 52(1):6.

PMID: 39663294 DOI: 10.1007/s10928-024-09953-4.


The Application of Nano Drug Delivery Systems in Female Upper Genital Tract Disorders.

van Staden D, Gerber M, Lemmer H Pharmaceutics. 2024; 16(11).

PMID: 39598598 PMC: 11597179. DOI: 10.3390/pharmaceutics16111475.


A Prospective Study of the Medication Regimen Complexity Index and Hospitalization Due to Adverse Drug Reactions Among People Living with HIV.

Poojar B, Kamath A, Rao S, Ullal S, Ramapuram J, Yadiyal M Medicina (Kaunas). 2024; 60(10).

PMID: 39459492 PMC: 11509384. DOI: 10.3390/medicina60101705.


Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer.

Schulz B, Leitner E, Schreiber T, Lindner T, Schwarz R, Aboutara N Cancers (Basel). 2024; 16(10).

PMID: 38791980 PMC: 11120498. DOI: 10.3390/cancers16101901.


References
1.
Shaqdan K, Aran S, Thrall J, Abujudeh H . Incidence of contrast medium extravasation for CT and MRI in a large academic medical centre: a report on 502,391 injections. Clin Radiol. 2014; 69(12):1264-72. DOI: 10.1016/j.crad.2014.08.004. View

2.
Brandle E, Gottwald E, Melzer H, Sieberth H . Influence of oral contraceptive agents on kidney function and protein metabolism. Eur J Clin Pharmacol. 1992; 43(6):643-6. DOI: 10.1007/BF02284965. View

3.
Anabtawi N, Drabison T, Hu S, Sparreboom A, Talebi Z . The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature. Expert Opin Drug Metab Toxicol. 2022; 18(7-8):459-468. DOI: 10.1080/17425255.2022.2113380. View

4.
Takita H, Barnett S, Zhang Y, Menochet K, Shen H, Ogungbenro K . PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter-Individual Variability. CPT Pharmacometrics Syst Pharmacol. 2020; 10(2):137-147. PMC: 7894406. DOI: 10.1002/psp4.12582. View

5.
Soldin O, Chung S, Mattison D . Sex differences in drug disposition. J Biomed Biotechnol. 2011; 2011:187103. PMC: 3051160. DOI: 10.1155/2011/187103. View